首页> 外文期刊>European review for medical and pharmacological sciences. >High expression of long non-coding RNA LOC730101 correlates with distant metastasis and exhibits a poor prognosis in patients with osteosarcoma
【24h】

High expression of long non-coding RNA LOC730101 correlates with distant metastasis and exhibits a poor prognosis in patients with osteosarcoma

机译:长的非编码RNA LOC730101的高表达与远处转移有关,并且在骨肉瘤患者中预后较差

获取原文
           

摘要

OBJECTIVE: Expression of long non-coding RNA LOC730101 (LOC730101) has been closely linked to the carcinogenesis of osteosarcoma and has been shown to function as a tumor promoter. However, the clinical significance of LOC730101 remains unknown. Our present study aimed to investigate the feasibility of LOC730101 as a novel prognostic biomarker for osteosarcoma. PATIENTS AND METHODS: Quantitative Real-time RT-PCR (qRT-PCR) was performed to examine LOC730101 expression in osteosarcoma tissues and adjacent non-cancerous tissues. The correlation between LOC730101 expression and clinicopathological features and the overall survival rate was determined. Cox regression analyses were performed to explore whether LOC730101 was an independent predictor of survival for osteosarcoma patients. RESULTS: We found that LOC730101 was significantly upregulated in human osteosarcoma tissues compared with corresponding adjacent normal tissues (p 0.01). Elevated LOC730101 expression was correlated with advanced clinical stage (p = 0.001) and distant metastasis (p = 0.005). Furthermore, survival assay revealed that osteosarcoma patients in the high LOC730101 expression group had significantly shorter 5-year overall survival time than those in the low LOC730101 expression group (p = 0.0002). In addition, multivariate analysis showed that LOC730101 maintained an independent prognostic influence on overall survival (p = 0.006). CONCLUSIONS: Our present study, for the first time, revealed that LOC730101 may serve as a poor prognostic indicator in patients with osteosarcoma.
机译:目的:长非编码RNA LOC730101(LOC730101)的表达与骨肉瘤的致癌作用密切相关,并已证明其可作为肿瘤的启动子。但是,LOC730101的临床意义仍然未知。我们目前的研究旨在调查LOC730101作为骨肉瘤的新型预后生物标志物的可行性。病人和方法:进行定量实时RT-PCR(qRT-PCR)来检查LOC730101在骨肉瘤组织和邻近非癌组织中的表达。确定了LOC730101表达与临床病理特征和总生存率之间的相关性。进行了Cox回归分析,以探讨LOC730101是否是骨肉瘤患者生存的独立预测指标。结果:与相应的邻近正常组织相比,我们发现人骨肉瘤组织中LOC730101显着上调(p <0.01)。 LOC730101表达升高与晚期临床阶段(p = 0.001)和远处转移(p = 0.005)相关。此外,生存分析表明,LOC730101高表达组的骨肉瘤患者的5年总生存时间明显短于LOC730101低表达组的患者(p = 0.0002)。此外,多因素分析表明,LOC730101对总体生存率具有独立的预后影响(p = 0.006)。结论:我们的本研究首次显示,LOC730101可以作为骨肉瘤患者的不良预后指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号